A multi-institutional team of researchers has reported the development of an anti-IL-8 antibody against endometriosis using recycling antibody engineering technology. The study confirmed the role of the inflammatory cytokine IL-8 in the development of inflammation and fibrosis in endometriosis and showed that administration of IL-8 antibodies in primate models improved endometriosis pathology. Read More
Prior to the COVID-19 pandemic, tuberculosis ranked as the leading cause of infectious disease deaths worldwide; the increase of multidrug-resistant Mycobacterium tuberculosis puts some pressure on the search for new tuberculosis therapeutic approaches. Researchers from Sanofi SA and their collaborators have published preclinical results on a sequanamycin – sequanamycin 9 (SEQ-9) – for the potential treatment of tuberculosis. Read More
Cessation Therapeutics Inc. has announced outcomes of a new study demonstrating that its anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl. The findings come from the company’s ongoing series of proof-of-concept studies in nonhuman primates. Read More
It has been demonstrated that stem cell factor (SCF) and its receptor KIT play key roles in the differentiation, proliferation, survival, migration and activation of mast cells, which in turn play a central role in the development of IgE-mediated allergic diseases, including allergic urticaria and food allergy. Read More
Incyclix Bio LLC has received FDA approval of an IND application for INX-315, a novel, potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for advanced or metastatic cancers. The first-in-human phase I/II study will be conducted in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer who have progressed on a CDK4/6 inhibitor regimen and CCNE1-amplified solid tumors that have progressed on standard-of-care treatment. Read More
THADA (thyroid adenoma associated) is a target gene of chromosomal aberration in thyroid adenomas, which has been previously identified as a type 2 diabetes mellitus (T2DM)-associated gene. Recently, researchers from Shandong University and affiliated organizations investigated the effects of THADA deficiency on glucose homeostasis. Read More
Atopic dermatitis (AD) is an inflammatory skin disease with complex pathogenesis. Researchers from the Swiss Institute of Allergy and Asthma Research and their collaborators have investigated biomarkers tied to AD and its severity. Read More
Previous studies indicated a protective function of TNFR2 signaling in multiple sclerosis (MS) as well as experimental autoimmune encephalomyelitis. Read More
Abbisko Therapeutics Co. Ltd. has patented epidermal growth factor receptor (EGFR; HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the nuclear medical countermeasures product development pipeline as a potential treatment for acute radiation syndrome (ARS). Read More
Crestone Inc. and the University of Colorado have reported efflux pump (bacterial) inhibitors potentially useful for the treatment of Gram-negative bacterial infections. Read More
Kiromic Biopharma Inc. has reported favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of Deltacel (KB-GDT-01) administered alone and in combination with a nonbiological antitumor therapy in mice. Read More
Mabwell (Shanghai) Bioscience Co. Ltd. has received approval of its IND application from Australia's Therapeutic Goods Administration (TGA) for 9MW3811 injection for tumors and pulmonary fibrosis. Read More
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders. Read More
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has signed a new sponsored research agreement (SRA) with the Vaccine and Immunotherapy Center at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a preclinical immuno-oncology study targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers. Read More
Tevard Biosciences Inc. has entered into a 4-year global research collaboration with Vertex Pharmaceuticals Inc. aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD) caused by nonsense mutations, with options to expand into additional muscular dystrophies and a second indication. Read More
Tricyclic fused pyrimidine compounds have been described in a Bristol Myers Squibb Co. patent as HER2 (erB2) and/or HER2 (erB2) mutant inhibitors with potential for the treatment of cancer. Read More
